A Functional Polymorphism of the μ-Opioid Receptor Gene is Associated with Naltrexone Response in Alcohol-Dependent Patients
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
This study examined the association between two specific polymorphisms of the gene encoding the mu-opioid receptor and treatment outcomes in alcohol-dependent patients who were prescribed naltrexone or placebo. A total of 82 patients (71 of European descent) who were randomized to naltrexone and 59 who were randomized to placebo (all of European descent) in one of three randomized, placebo-controlled clinical trials of naltrexone were genotyped at the A(+118)G (Asn40Asp) and C(+17)T (Ala6Val) SNPs in the gene encoding the mu-opioid receptor (OPRM1). The association between genotype and drinking outcomes was measured over 12 weeks of treatment. In subjects of European descent, individuals with one or two copies of the Asp40 allele treated with naltrexone had significantly lower rates of relapse (p=0.044) and a longer time to return to heavy drinking (p=0.040) than those homozygous for the Asn40 allele. There were no differences in overall abstinence rates (p=0.611), nor were there differences in relapse rates or abstinence rates between the two genotype groups among those assigned to placebo. These preliminary results are consistent with prior literature demonstrating that the opioid system is involved in the reinforcing properties of alcohol and that allelic variation at OPRM1 is associated with differential response to a mu-receptor antagonist. If replicated, these results would help to identify alcohol-dependent individuals who may be most likely to respond to treatment wit…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An initial retrospective analysis of NTX trials found that OPRM1 influenced treatment response, such that individuals with the Asp40 variant (G allele) receiving NTX had a longer time until the first heavy drinking day and were half as likely to relapse compared to those homozygous for the Asn40 variant (A allele) [92].”
From Relapse prevention for addictive behaviors (2011) · cites this paper as [92]
In the citing paper
“Interestingly, both human A118G subjects and Rhesus C77G subjects are more likely to respond positively to opioid antagonist therapy for alcoholism, which suggests that the differences in receptor properties may be a direct physiological mechanism for the increased risk for alcoholism (Oslin et al 2003).”
From The behavioral, anatomical and pharmacological parallels between social attachment, love and addiction (2012) · cites this paper as Oslin et al 2003
Citations
Cites
(1996) · Cited by 6,884
The fifth edition of the addiction severity index
McLellan, A. T., Kushner, H., Metzger, D., Peters, R., Smith, I., Grissom, G., Pettinati, H., & Argeriou, M. (1992) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(92)90062-s · Cited by 4,222 · cited 1×
“The Addiction Severity Index (ASI) was used to measure the severity of alcoholrelated problems during the pretreatment period (McLellan et al, 1980, 1992).”
MethodSelf-citationSobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110 · cited 1×
“The Time Line Follow-Back (TLFB) method measured alcohol consumption (Sobell et al, 1988; Sobell and Sobell, 1992) during the pretreatment and treatment periods.”
MethodMcLELLAN, A. T., LUBORSKY, L., WOODY, G. E., & O??BRIEN, C. P. (1980) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198001000-00006 · Cited by 3,188
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Self-citationNew Data from the Addiction Severity Index Reliability and Validity in Three Centers
McLELLAN, A. T., LUBORSKY, L., CACCIOLA, J., GRIFFITH, J., EVANS, F., BARR, H. L., & OʼBRIEN, C. P. (1985) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198507000-00005 · Cited by 1,503 · cited 1×
“…lifetime and recent (past 30 days) severity of problems in seven areas of biopsychosocial functioning (represented by component scores): medical status, employment and self-support, alcohol use, drug use, legal status, family and social relations, and psychiatric symptoms (McLellan et al, 1985).”
BackgroundSelf-citationNaltrexone and Coping Skills Therapy for Alcohol Dependence: A Controlled Study
O'Malley, S. S. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110045007 · Cited by 1,487 · cited 4×
“Although this definition of heavy drinking has been used in a number of pharmacotherapy trials (O’Malley et al, 1992; Volpicelli et al, 1992; Anton, 1996; Kranzler and VanKirk, 2001), both higher and lower levels of consumption could be considered significant.”
BackgroundMethodInfluentialBond, C., LaForge, K. S., Tian, M., Melia, D., Zhang, S., Borg, L., Gong, J., Schluger, J., Strong, J. A., Leal, S. M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9608 · Cited by 1,074 · cited 3×
“…association between OPRM1 sequence variation and the presence of alcohol and/or drug dependence (Bergen et al, 1997; Berrettini et al, 1997; Bond et al, 1998; Kranzler et al, 1998; Sander et al, 1998; Gelernter et al, 1999; Town et al, 1999; Hoehe et al, 2000; Franke et al, 2001;…”
BackgroundInfluentialSOBELL, L. C., SOBELL, M. B., LEO, G. I., & CANCILLA, A. (1988) · British Journal of Addiction · doi:10.1111/j.1360-0443.1988.tb00485.x · Cited by 776 · cited 1×
“The Time Line Follow-Back (TLFB) method measured alcohol consumption (Sobell et al, 1988; Sobell and Sobell, 1992) during the pretreatment and treatment periods.”
MethodNaltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618 · cited 1×
“…advantage of naltrexone over placebo (O’Malley et al, 1992; Volpicelli et al, 1992; Oslin et al, 1997; Chick et al, 2000; Anton et al, 2001; Monti et al, 2001; Morris et al, 2001), other studies have failed to show a significant drugplacebo difference (Kranzler et al, 2000; Krystal et al, 2001).”
Background
Research works printed but not linked: 2
- Thomas C, Wallack S, Swift R, Bishop C, McCarty D, Simoni-Wastila L (2001). Adoption of naltrexone in alcoholism treatment. J Addict Dis 20: 180.
- Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP (1997). BRENDA Manual: Compliance Enhancement Techniques with Pharmacotherapy for Alcohol and Drug Dependence. Guilford press: Philadelphia.
Cited by
DSM-5 criteria for substance use disorders: recommendations and rationale
Hasin, D. S., O’Brien, C. P., Auriacombe, M., Borges, G., Bucholz, K., Budney, A., Compton, W. M., Crowley, T., Ling, W., Petry, N. M., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12060782 · Cited by 1,622
“, OPRM1 A118G and naltrexone response [124, 125]) Positron emission tomography (PET) imaging of brain functioning indicates that dopamine is associated with substance use (126, 127).”
BackgroundSelf-citationOpioid antagonists for alcohol dependence
Srisurapanont, M., & Jarusuraisin, N. (2002) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867 · Cited by 764
Should addictive disorders include non-substance-related conditions?
Potenza, M. N. (2006) · Addiction · doi:10.1111/j.1360-0443.2006.01591.x · Cited by 663
“As genetic factors have been associated with positive outcome for treatment of SUDs [81], genetic sampling should be considered in treatment trials in PG and other ICDs.”
BackgroundAlcoholism: A Systems Approach From Molecular Physiology to Addictive Behavior
Spanagel, R. (2009) · Physiological Reviews · doi:10.1152/physrev.00013.2008 · Cited by 634
The behavioral economics of substance use disorders: reinforcement pathologies and their repair
Bickel, W. K., Johnson, M. W., Koffarnus, M. N., MacKillop, J., & Murphy, J. G. (2014) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032813-153724 · Cited by 655
“…a single nucleotide polymorphism in the OPRM1 gene (rs1799971) is associated with greater sensitivity to alcohol’s subjective effects (Ray & Hutchison 2004, 2007) and naltrexone’s clinical effects (Anton et al. 2008, Kim et al. 2009, Oslin et al. 2003), participants were genotyped for this locus.”
BackgroundAllelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G
Zhang, Y., Wang, D., Johnson, A. D., Papp, A. C., & Sadée, W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504942200 · Cited by 563
The neurobiology of pathological gambling and drug addiction: an overview and new findings
Potenza, M. N. (2008) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2008.0100 · Cited by 508
Relapse prevention for addictive behaviors
Hendershot, C. S., Witkiewitz, K., George, W. H., & Marlatt, G. A. (2011) · Substance Abuse Treatment, Prevention, and Policy · doi:10.1186/1747-597x-6-17 · Cited by 467
“An initial retrospective analysis of NTX trials found that OPRM1 influenced treatment response, such that individuals with the Asp40 variant (G allele) receiving NTX had a longer time until the first heavy drinking day and were half as likely to relapse compared to those homozygous for the Asn40 variant (A allele) [92…”
BackgroundOpioid dependence and addiction during opioid treatment of chronic pain
Ballantyne, J. C., & LaForge, S. K. (2007) · Pain · doi:10.1016/j.pain.2007.03.028 · Cited by 447
“Several studies have consistently shown that the A118G variant affects opioid-mediated control of the hypothalamic-pituitary-adrenal (HPA) stress-responsive axis and that this may have implications for the treatment of alcoholism with opioid antagonists (Wand et al., 2002; Oslin et al., 2003).”
BackgroundAnton, R. F., Oroszi, G., O’Malley, S., Couper, D., Swift, R., Pettinati, H., & Goldman, D. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.2.135 · Cited by 451
Self-citationAnticraving Medications for Relapse Prevention: A Possible New Class of Psychoactive Medications
O’Brien, C. P. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1423 · Cited by 405
Self-citationPharmacogenetics and Human Molecular Genetics of Opiate and Cocaine Addictions and Their Treatments
Kreek, M. J., Bart, G., Lilly, C., Laforge, K. S., & Nielsen, D. A. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.1.1 · Cited by 391
“Also, 118A/118G or 118G/118G genotypes have been reported to be associated with an improved response to treatment of alcoholism with naltrexone (Oslin et al., 2003) as well as to treatment of smoking with transdermal nicotine replacement therapy (Lerman et al., 2004).”
BackgroundPharmacological treatment of alcohol dependence: Target symptoms and target mechanisms
HEILIG, M., & EGLI, M. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.02.001 · Cited by 377
“To complete the chain of evidence, the 118G allele has recently been found to be a predictor of treatment response to NTX in alcohol dependent subjects (Oslin et al., 2003).”
BackgroundRelatively strong automatic appetitive action‐tendencies in male carriers of the OPRM1 G‐allele
Wiers, R. W., Rinck, M., Dictus, M., & Van Den Wildenberg, E. (2009) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2008.00454.x · Cited by 377
“Furthermore, there is some evidence that carriers of a g-allele respond better to the opioid receptor antagonist naltrexone than alcohol-dependent patients without a g-allele (Anton et al. 2008; Oslin et al. 2003; Ray & Hutchison 2007), but findings have not been consistent (Gelernter et al.”
BackgroundThe Neurobiology of Substance and Behavioral Addictions
Grant, J. E., Brewer, J. A., & Potenza, M. N. (2006) · CNS Spectrums · doi:10.1017/s109285290001511x · Cited by 372
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“A functional polymorphism, Asp40 allele, of the mu opioid receptor gene has been shown to predict naltrexone treatment response in alcohol-dependent individuals (Anton et al., 2008; Kim et al., 2009; Oroszi et al., 2009; Oslin et al., 2003) (Ib), but its impact may be moderated by other efficacious treatment or patien…”
BackgroundHeterogeneity of Alcohol Use Disorder: Understanding Mechanisms to Advance Personalized Treatment
Litten, R. Z., Ryan, M. L., Falk, D. E., Reilly, M., Fertig, J. B., & Koob, G. F. (2015) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.12669 · Cited by 330
Somogyi, A. A., Barratt, D. T., & Coller, J. K. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100095 · Cited by 324
Identifying the neural circuitry of alcohol craving and relapse vulnerability
Heinz, A., Beck, A., Grüsser, S. M., Grace, A. A., & Wrase, J. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00136.x · Cited by 314
“…alcoholics and lower the amount of consumed alcohol (Streeton & Whelan 2001; Srisurapanont & Jarusuraisin 2005), but see (Krystal et al. 2001), particularly if applied in patients with a potential high affinity, gain-of-function m-opiate receptor genotype (Oslin et al. 2003; Ray & Hutchison 2007).”
BackgroundRay, L. A., & Hutchison, K. E. (2004) · Alcoholism: Clinical and Experimental Research · doi:10.1097/01.alc.0000148114.34000.b9 · Cited by 310
Burkett, J. P., & Young, L. J. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2794-x · Cited by 307
The Genetic Basis of Addictive Disorders
Ducci, F., & Goldman, D. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2012.03.010 · Cited by 303
A genetic determinant of the striatal dopamine response to alcohol in men
Ramchandani, V. A., Umhau, J., Pavon, F. J., Ruiz-Velasco, V, Margas, W., Sun, H., Damadzic, R., Eskay, R., Schoor, M., Thorsell, A., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.56 · Cited by 298
Opioid antagonists for alcohol dependence
Srisurapanont, M., & Jarusuraisin, N. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867.pub2 · Cited by 265
Exposure to the Taste of Alcohol Elicits Activation of the Mesocorticolimbic Neurocircuitry
Filbey, F. M., Claus, E., Audette, A. R., Niculescu, M., Banich, M. T., Tanabe, J., Du, Y. P., & Hutchison, K. E. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301513 · Cited by 270
“In addition, genetic variation in GABA function (Edenberg et al, 2004; Covault et al, 2004), opioid function (Ray and Hutchison, 2004; Oslin et al, 2003), dopamine function (Hutchison et al, 2003; Hutchison et al, 2006) and cannabinoid function (Zhang et al, 2004) have also been linked to the…”
BackgroundUpdate on neuropharmacological treatments for alcoholism: Scientific basis and clinical findings
Johnson, B. A. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.005 · Cited by 264
Neurobiology of addiction: treatment and public policy ramifications
Dackis, C., & O'Brien, C. (2005) · Nature Neuroscience · doi:10.1038/nn1105-1431 · Cited by 267
Self-citationGambling Disorder and Other Behavioral Addictions: Recognition and Treatment
Yau, Y. H. C., & Potenza, M. N. (2015) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000051 · Cited by 267
Current Status of Co-Occurring Mood and Substance Use Disorders: A New Therapeutic Target
Pettinati, H. M., O’Brien, C. P., & Dundon, W. D. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12010112 · Cited by 252
Self-citationRay, L. A., & Hutchison, K. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.9.1069 · Cited by 258
“Efforts to identify genetic variants that may moderate the effects of naltrexone have focused on the gene coding for μ-opioid receptors (ie, the OPRM1 gene), which are the primary target of naltrexone.(29,30) One of the most widely studied polymorphisms of the OPRM1 gene is the A118G single nucleotide polymorphism (SN…”
BackgroundPharmacogenetic approaches to the treatment of alcohol addiction
Heilig, M., Goldman, D., Berrettini, W., & O'Brien, C. P. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3110 · Cited by 248
Self-citationOpioid antagonists for alcohol dependence
Rösner, S., Hackl-Herrwerth, A., Leucht, S., Vecchi, S., Srisurapanont, M., & Soyka, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867.pub3 · Cited by 247
Genetic approaches to addiction: genes and alcohol
Ducci, F., & Goldman, D. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02203.x · Cited by 246
Hansson, A. C., Cippitelli, A., Sommer, W. H., Fedeli, A., Björk, K., Soverchia, L., Terasmaa, A., Massi, M., Heilig, M., & Ciccocioppo, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604419103 · Cited by 249
Stress, alcohol and drug interaction: an update of human research
Uhart, M., & Wand, G. S. (2009) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00131.x · Cited by 234
“…may be of clinical relevance that one study has demonstrated that 12 weeks of naltrexone treatment led to significantly lower relapse rates in alcohol-dependent persons with the 118G allele, who also took longer to resume drinking than did individuals with only the 118A allele (Oslin et al. 2003).”
BackgroundOswald, L. M., & Wand, G. S. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.02.008 · Cited by 234
“[224] recently reported a differential response to 12 weeks of naltrexone treatment in alcohol-dependent participants as a function of the A118G polymorphism.”
BackgroundChamorro, A., Marcos, M., Mirón‐Canelo, J., Pastor, I., González‐Sarmiento, R., & Laso, F. (2012) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00442.x · Cited by 153
“This field of research, however, has great potential for improving costeffectiveness of naltrexone and reducing unnecessary exposure to this drug (Oslin et al. 2003).”
BackgroundResultInfluentialBart, G., Kreek, M. J., Ott, J., LaForge, K. S., Proudnikov, D., Pollak, L., & Heilig, M. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300598 · Cited by 220
“This hypothesis has recently received some support by the finding that alcohol-dependent subjects with an 118G allele return to heavy drinking following treatment with naltrexone later than do similarly treated alcoholics with the prototypic receptor (Oslin et al, 2003).”
BackgroundNeuroscience of Behavioral and Pharmacological Treatments for Addictions
Potenza, M. N., Sofuoglu, M., Carroll, K. M., & Rounsaville, B. J. (2011) · Neuron · doi:10.1016/j.neuron.2011.02.009 · Cited by 214
“, a functional variant of the gene encoding the mu-opioid receptor has been associated with opioid antagonist treatment outcome in some (Oslin et al., 2003) but not other (Arias et al.”
Kroslak, T., LaForge, K. S., Gianotti, R. J., Ho, A., Nielsen, D. A., & Kreek, M. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04738.x · Cited by 213
Is there a case for extended interventions for alcohol and drug use disorders?
McKay, J. R. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01208.x · Cited by 211
Medications development to treat alcohol dependence: a vision for the next decade
Litten, R. Z., Egli, M., Heilig, M., Cui, C., Fertig, J. B., Ryan, M. L., Falk, D. E., Moss, H., Huebner, R., & Noronha, A. (2012) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00454.x · Cited by 202
“For example, Oslin et al. (2003) first suggested that the A118G variant of the m-opioid receptor gene (OPRM1) is associated with greater reductions in drinking in alcohol-dependent patients treated with naltrexone.”
Addiction science: Uncovering neurobiological complexity
Volkow, N. D., & Baler, R. D. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.007 · Cited by 193
“In terms of treating alcohol-dependent individuals, carriers of the A118G (OPRM1) polymorphism have better clinical responses on NTX, including lower relapse rates, compared with carriers of the A allele (Anton et al., 2008; Oslin et al., 2003).”
BackgroundGelernter, J., Gueorguieva, R., Kranzler, H. R., Zhang, H., Cramer, J., Rosenheck, R., Krystal, J. H., & the VA Cooperative Study #425 Study Group (2007) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00339.x · Cited by 200
“First, although the patient sample available to us was larger than that ascertained in a prior positive study (Oslin et al., 2003) (which considered 71 NTX-treated and 59 placebotreated EA subjects), it is still possible, as noted above, that we failed to observe a true effect because of the limited statistical power.”
ResultSelf-citationThe genetics of addiction—a translational perspective
Agrawal, A., Verweij, K. J. H., Gillespie, N. A., Heath, A. C., Lessov-Schlaggar, C. N., Martin, N. G., Nelson, E. C., Slutske, W. S., Whitfield, J. B., & Lynskey, M. T. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.54 · Cited by 197
Filbey, F. M., Ray, L., Smolen, A., Claus, E. D., Audette, A., & Hutchison, K. E. (2008) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00692.x · Cited by 192
“…should be interpreted in the context of the clinical literature suggesting that carriers of the G allele are more responsive to naltrexone, an opiate blocker thought to act selectively for l-opioid receptors, as a pharmacotherapy for alcoholism (Oslin et al., 2003; Ray and Hutchison, 2007).”
Lerman, C., Wileyto, E. P., Patterson, F., Rukstalis, M., Audrain-McGovern, J., Restine, S., Shields, P. G., Kaufmann, V, Redden, D., Benowitz, N., et al. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500238 · Cited by 195
Self-citationVariation at the mu-opioid receptor gene ( OPRM1 ) influences attachment behavior in infant primates
Barr, C. S., Schwandt, M. L., Lindell, S. G., Higley, J. D., Maestripieri, D., Goldman, D., Suomi, S. J., & Heilig, M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710225105 · Cited by 191
Shared Genetic Contributions to Pathological Gambling and Major Depression in Men
Potenza, M. N., Xian, H., Shah, K., Scherrer, J. F., & Eisen, S. A. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.1015 · Cited by 191
The genetic epidemiology of substance use disorder: A review
Prom-Wormley, E. C., Ebejer, J., Dick, D. M., & Bowers, M. S. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2017.06.040 · Cited by 175
“Genetic screening may identify individuals who will best respond to naltrexone for the reduction of problem drinking (Anton et al., 2008; Oslin et al., 2003).”
BackgroundLong-acting injectable naltrexone for the treatment of alcohol dependence
Mannelli, P., Peindl, K., Masand, P. S., & Patkar, A. A. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.10.1265 · Cited by 183
Predicting response to opiate antagonists and placebo in the treatment of pathological gambling
Grant, J. E., Kim, S. W., Hollander, E., & Potenza, M. N. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1235-3 · Cited by 176
Van Den Wildenberg, E., Wiers, R. W., Dessers, J., Janssen, R. G. J. H., Lambrichs, E. H., Smeets, H. J. M., & Van Breukelen, G. J. P. (2007) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2006.00258.x · Cited by 181
Bart, G., Heilig, M., LaForge, K. S., Pollak, L., Leal, S. M., Ott, J., & Kreek, M. J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001504 · Cited by 177
Arias, A., Feinn, R., & Kranzler, H. R. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.11.024 · Cited by 177
Self-citationThe Status of Naltrexone in the Treatment of Alcohol Dependence: Specific Effects on Heavy Drinking
Pettinati, H. M., O'Brien, C. P., Rabinowitz, A. R., Wortman, S. P., Oslin, D. W., Kampman, K. M., & Dackis, C. A. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000245566.52401.20 · Cited by 169
Self-citationCiccocioppo, R., Economidou, D., Cippitelli, A., Cucculelli, M., Ubaldi, M., Soverchia, L., Lourdusamy, A., & Massi, M. (2006) · Addiction Biology · doi:10.1111/j.1369-1600.2006.00032.x · Cited by 166
“…D2, µ-opioid receptor, and serotonin transporter genes have also been associated with increased vulnerability to develop alcoholism and with a different responses to pharmacological interventions (Lawford et al. 1995; Oslin et al. 2003; Edenberg & Kranzler 2005; Feinn, Nellissery & Kranzler 2005).”
BackgroundKalman, D., Kim, S., DiGirolamo, G., Smelson, D., & Ziedonis, D. (2010) · Clinical Psychology Review · doi:10.1016/j.cpr.2009.08.009 · Cited by 165
“In a study of treatment for alcohol dependence, Oslin et al. (2003) found that naltrexone response was associated with a polymorphism in the mu-opioid receptor gene, OPRMI.”
BackgroundGenetic Impairment of Frontocortical Endocannabinoid Degradation and High Alcohol Preference
Hansson, A. C., Bermúdez-Silva, F. J., Malinen, H., Hyytiä, P., Sanchez-Vera, I., Rimondini, R., Rodriguez de Fonseca, F., Kunos, G., Sommer, W. H., & Heilig, M. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301034 · Cited by 163
Alcohol Biomarkers in Applied Settings: Recent Advances and Future Research Opportunities
Litten, R. Z., Bradley, A. M., & Moss, H. B. (2010) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01170.x · Cited by 159
“…phenotypes is expected to provide models for the multiple subtypes of alcohol dependence (Ait-Daoud et al., 2009; Mayfield and Harris, 2009; Oslin et al., 2003), enabling clinicians to identify patients who are likely to respond positively or negatively to specific treatments, especially…”
BackgroundDrugs for relapse prevention of alcoholism: ten years of progress
Spanagel, R., & Kiefer, F. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.12.005 · Cited by 168
Medication treatment of different types of alcoholism
Johnson, B. A. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.08101500 · Cited by 151
Genes Associated With Addiction: Alcoholism, Opiate, and Cocaine Addiction
Kreek, M. J., Nielsen, D. A., & LaForge, K. S. (2004) · NeuroMolecular Medicine · doi:10.1385/nmm:5:1:085 · Cited by 159
The genetics of the opioid system and specific drug addictions
Levran, O., Yuferov, V., & Kreek, M. J. (2012) · Human Genetics · doi:10.1007/s00439-012-1172-4 · Cited by 143
“This prediction has been supported by several studies showing that AD subjects with the 118G allele have better clinical response (Anton et al. 2008; Oroszi et al. 2009; Oslin et al. 2003; Ray and Hutchison 2007).”
ResultAre μ-opioid receptor polymorphisms important for clinical opioid therapy?
Lötsch, J., & Geißlinger, G. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.12.006 · Cited by 146
The Mu-Opioid Receptor Polymorphism A118G Predicts Cortisol Responses to Naloxone and Stress
Chong, R. Y., Oswald, L. M., Yang, X., Uhart, M., Lin, P., & Wand, G. S. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300856 · Cited by 148
“Also, Oslin et al (2003) showed that alcoholdependent persons carrying the G allele are more likely to respond to treatment with the opioid antagonist, naltrexone, than those homozygous for the A allele.”
BackgroundOPRM1 SNP (A118G): Involvement in disease development, treatment response, and animal models
Mague, S. D., & Blendy, J. A. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.12.016 · Cited by 136
“Subsequent studies investigating the involvement of this SNP in naltrexone response have replicated these initial findings (Anton et al., 2008; Kim et al., 2009; Oroszi et al., 2009; Oslin et al., 2003).”
BackgroundResultTidey, J. W., Monti, P. M., Rohsenow, D. J., Gwaltney, C. J., Miranda, R., McGeary, J. E., MacKillop, J., Swift, R. M., Abrams, D. B., Shiffman, S., et al. (2008) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2007.00545.x · Cited by 136
“Participants were grouped by OPRM1 status using the convention reported by Oslin et al. (2003), with the Asp40 variant group consisting of participants who were either heterozygous or homozygous for the Asp40 variant and the Asn40 group consisting of those homozygous for the Asn40 variant.”
BackgroundMethodResultAnton, R. F., Drobes, D. J., Voronin, K., Durazo-Avizu, R., & Moak, D. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1720-7 · Cited by 135
“This may be related to genetic (Oslin et al. 2003) or some neurochemical differences which manifest over years of heavy alcohol consumption.”
BackgroundOslin, D. W., Cary, M., Slaymaker, V., Colleran, C., & Blow, F. C. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.03.009 · Cited by 125
Self-citationRay, L. A., Mackillop, J., & Monti, P. M. (2010) · Substance Use & Misuse · doi:10.3109/10826084.2010.482427 · Cited by 126
“The relationship was such that individuals with at least one copy of the variant allele (the A118G SNP of the OPRM1 gene) showed lower relapse rates and longer time to return to heavy drinking when treated with naltrexone (Oslin et al., 2003).”
InfluentialEvidence-based treatments of addiction
O'Brien, C. P. (2008) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2008.0105 · Cited by 123
Self-citationPharmacotherapy of Alcohol Use Disorders: Seventy-Five Years of Progress
Zindel, L. R., & Kranzler, H. R. (2014) · Journal of Studies on Alcohol and Drugs, Supplement · doi:10.15288/jsads.2014.75.79 · Cited by 128
“In some naltrexone studies, for example, carriers of a variant (118G or Asp40) allele in OPRM1, the gene encoding the μ-opioid receptor, had a better clinical response to naltrexone than 118A (or Asn40) allele homozygotes (Anton et al., 2008; Oslin et al. 2003).”
BackgroundSelf-citationApproach to the genetics of alcoholism: A review based on pathophysiology
Köhnke, M. D. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.021 · Cited by 153
Association of OPRM1 A118G variant with the relative reinforcing value of nicotine
Ray, R., Jepson, C., Patterson, F., Strasser, A. A., Rukstalis, M. R., Perkins, K. A., Lynch, K. G., O’Malley, S. S., Berrettini, W. H., & Lerman, C. E. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0504-2 · Cited by 131
Self-citationRay, L. A., Miranda, R., Tidey, J. W., McGeary, J. E., MacKillop, J., Gwaltney, C. J., Rohsenow, D. J., Swift, R. M., & Monti, P. M. (2010) · Journal of Abnormal Psychology · doi:10.1037/a0017550 · Cited by 123
Alcoholism: genes and mechanisms
Oroszi, G., & Goldman, D. (2004) · Pharmacogenomics · doi:10.1517/14622416.5.8.1037 · Cited by 123
Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial
Oslin, D. W., Leong, S. H., Lynch, K. G., Berrettini, W., O’Brien, C. P., Gordon, A. J., & Rukstalis, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.3053 · Cited by 118
Self-citationSöderpalm, B., & Ericson, M. (2011) · Current topics in behavioral neurosciences · doi:10.1007/978-3-642-28720-6_170 · Cited by 133
Genetics of alcohol dependence
Gelernter, J., & Kranzler, H. R. (2009) · Human Genetics · doi:10.1007/s00439-009-0701-2 · Cited by 119
“Oslin et al. (2003), in a study of 130 EA subjects from three placebocontrolled trials, found that naltrexone-treated patients with one or more Asp40 alleles were signiWcantly less likely than Asn40 homozygotes to relapse to heavy drinking.”
Self-citationTroisi, A., Frazzetto, G., Carola, V., Di Lorenzo, G., Coviello, M., D'Amato, F. R., Moles, A., Siracusano, A., & Gross, C. (2011) · Social Neuroscience · doi:10.1080/17470919.2010.482786 · Cited by 118
“…pain threshold (Sia et al., 2008), increased sensitivity to euphorogenic effects of addictive drugs (Ray & Hutchison, 2004), increased cortisol response after challenge with naltrexone (Chong et al., 2006), and higher rates of therapeutic response to naltrexone in alcoholism (Oslin et al., 2003).”
BackgroundAlcohol Use Disorder: Neurobiology and Therapeutics
Yang, W., Singla, R., Maheshwari, O., Fontaine, C. J., & Gil‐Mohapel, J. (2022) · Biomedicines · doi:10.3390/biomedicines10051192 · Cited by 140
The Effect of Olanzapine on Craving and Alcohol Consumption
Hutchison, K. E., Ray, L. A., Sandman, E., Goodworth, M.-C. R., Peters, A., Davidson, D., & Swift, R. M. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300917 · Cited by 126
“For example, preliminary work has suggested that naltrexone is more effective for individuals with a genetic variant that changes the binding profile of the m-opioid receptor (eg Oslin et al, 2003).”
BackgroundHeilig, M., Thorsell, A., Sommer, W. H., Hansson, A. C., Ramchandani, V. A., George, D. T., Hommer, D., & Barr, C. S. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.11.018 · Cited by 117
“Some secondary analyses of published clinical trials also suggest that OPRM1 118G carriers are particularly responsive to naltrexone (Oslin et al., 2003; Anton et al., 2008), but results have not been consistent (Gelernter et al., 2007).”
BackgroundResultHuang, P., Chen, C., Mague, S. D., Blendy, J. A., & Liu‐Chen, L. (2011) · Biochemical Journal · doi:10.1042/bj20111050 · Cited by 117
Evidence-Based Pharmacological Treatment of Substance Use Disorders and Pathological Gambling
van den Brink, W. (2012) · Current Drug Abuse Reviews · doi:10.2174/1874473711205010003 · Cited by 116
Crist, R. C., & Berrettini, W. H. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.10.018 · Cited by 124
Self-citationManagement of Alcohol Dependence in Patients with Liver Disease
Addolorato, G., Mirijello, A., Leggio, L., Ferrulli, A., & Landolfi, R. (2013) · CNS Drugs · doi:10.1007/s40263-013-0043-4 · Cited by 110
Nylander, I., & Roman, E. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3217-3 · Cited by 99
“…in the effects of naltrexone such as the ability to reduce ethanol consumption is well known, and besides the previously described influence of genotype (Mague and Blendy 2010; Oslin et al. 2003), this study shows that early-life conditions also affect the outcome of naltrexone treatment.”
BackgroundDrakenberg, K., Nikoshkov, A., Horváth, M. C., Fagergren, P., Gharibyan, A., Saarelainen, K., Rahman, S., Nylander, I., Bakalkin, G., Rajs, J., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600871103 · Cited by 109
Schacht, J. P., Randall, P. K., Latham, P. K., Voronin, K. E., Book, S. W., Myrick, H., & Anton, R. F. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.74 · Cited by 110
“Several initial randomized clinical trials (RCTs; Anton et al, 2008; Chamorro et al, 2012; Oslin et al, 2003), including a post hoc analysis of the COMBINE study (Anton et al, 2008), reported greater NTX efficacy among individuals who carried the A118G G (Asp) allele, which ~ 25% of Caucasians and…”
BackgroundPharmacotherapy for alcohol dependence: status of current treatments
Franck, J., & Jayaram-Lindström, N. (2013) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2013.05.005 · Cited by 107
Barr, C. S., Schwandt, M., Lindell, S. G., Chen, S. A., Goldman, D., Suomi, S. J., Higley, J. D., & Heilig, M. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.369 · Cited by 105
Genetic Moderators of Naltrexone's Effects on Alcohol Cue Reactivity
McGeary, J. E., Monti, P. M., Rohsenow, D. J., Tidey, J. W., Swift, R. M., & Miranda, R. (2006) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2006.00156.x · Cited by 107
Different lengths of times for progressions in adolescent substance involvement
Ridenour, T. A., Lanza, S. T., Donny, E. C., & Clark, D. B. (2006) · Addictive Behaviors · doi:10.1016/j.addbeh.2006.03.015 · Cited by 109
“Rather, they result from the interaction between drug-related constructs and individuals’ characteristics including genetic and environmental influences (Cook et al., 2005;Ellenbroek et al., 2005;Mulligan et al., 2003;Oslin et al., 2003).”
BackgroundDeb, I., Chakraborty, J., Gangopadhyay, P. K., Choudhury, S. R., & Das, S. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06472.x · Cited by 119
“Alcoholic patients with one or two copies of the Asp40 allele when treated with the opioid antagonist naltrexone showed better clinical outcomes compared with subjects homozygous for the Asn40 allele (Oslin et al. 2003).”
BackgroundFamily History of Alcoholism Influences Naltrexone-Induced Reduction in Alcohol Drinking
Krishnan‐Sarin, S., Krystal, J. H., Shi, J. M., Pittman, B. P., & O’Malley, S. S. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.11.018 · Cited by 105
“…in subgroups f alcohol-dependent patients (Gueorguieva et al. 2006; Kiefer et l. 2005), such as those with an early onset or a positive family istory (FH) of alcoholism (Monterosso et al. 2001; Rubio et al. 005) or particular polymorphisms of the opioid receptor gene PRM1 (Oslin et al. 2003).”
BackgroundPharmacotherapy and other treatments for cocaine abuse and dependence
Vocci, F. J., & Elkashef, A. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165596.98552.02 · Cited by 100
O’Malley, S. S., Robin, R. W., Levenson, A. L., GreyWolf, I., Chance, L. E., Hodgkinson, C. A., Romano, D., Robinson, J., Meandzija, B., Stillner, V., et al. (2008) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00682.x · Cited by 101
“These findings in a group controlled for OPRM1 genotype are consistent with the main effect of naltrexone on reduced risk of relapse even when controlling for genotype in studies by Oslin et al. (2003) and Gelernter (Gelernter et al., 2007).”
Chatterjee, S., & Bartlett, S. E. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710790966597 · Cited by 103
Metadata
- Authors
- Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P.
- Affiliations
- University of Pennsylvania (US)
- University of Connecticut (US)
- Yale University (US)
- Corresponding author
- Oslin, David W
- Venue
- Neuropsychopharmacology
- Published
- 2003-04-23
- Volume
- 28
- Issue
- 8
- Pages
- 1546-1552
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2074406420
- Cited by
- 571
- References
- 50
- Citations by year
- 2026: 2 · 2025: 10 · 2024: 4 · 2023: 3 · 2022: 7 · 2021: 9 · 2020: 13 · 2019: 18 · 2018: 13 · 2017: 13 · 2016: 20 · 2015: 31 · 2014: 36 · 2013: 34 · 2012: 58
- FWCI
- 10.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- University of Pennsylvania
- National Alliance for Research on Schizophrenia and Depression
- National Institutes of Health (5r01aa011062-05, AA03510)
- U.S. Public Health Service
- National Institute on Alcohol Abuse and Alcoholism (AA11330, AA-07517, R01AA011330, AA 13736, AA-03510, K24AA013736, AA 11062)
- National Institute of Mental Health (K08MH001599, MH 01599)
- National Institute on Drug Abuse (R01DA014008, DA 11385, DA 14008, DA001586)
- National Center for Research Resources (RR-06192, M01RR006192)
- NIH Clinical Center
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- mu-opioid receptor, OPRM1, naltrexone, alcoholism, genetic polymorphism, treatment response, relapse, abstinence, opioid system, pharmacogenetics
- MeSH terms
- Adult, Alcoholism, Female, Gene Frequency, Humans, Male, Middle Aged, Naltrexone, Polymorphism, Genetic, Confidence Intervals, Logistic Models, Odds Ratio, Survival Analysis, Receptors, Opioid, mu
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.